摘要
目的探讨安罗替尼联合吉西他滨+顺铂(GP)方案治疗复发或转移鼻咽癌患者的效果及安全性。方法回顾性病例对照研究。回顾性分析2020年1月至2021年12月广西科技大学第二附属医院和来宾市人民医院82例初诊远处转移或根治性放化疗后复发转移的鼻咽癌患者的临床资料,安罗替尼联合GP方案治疗(治疗组)45例,同期行GP方案治疗(对照组)37例。比较两组患者的近期疗效和不良反应。采用Kaplan-Meier法比较两组无进展生存(PFS)、总生存(OS),并进行log-rank检验。采用Cox比例风险模型分析PFS的影响因素。结果82例患者中,男性63例,女性19例,年龄(48±10)岁。治疗组的客观缓解率和疾病控制率均高于对照组[71.11%(32/45)比62.16%(23/37),86.67%(39/45)比81.08%(30/37)],但差异均无统计学意义(均P>0.05)。两组患者中位PFS时间为23.53个月(95%CI:17.48~29.58个月)比17.40个月(95%CI:13.33~21.47个月),两组PFS比较差异有统计学意义(P<0.05);中位OS时间为34.03个月(95%CI:29.42~38.64个月)比30.47个月(95%CI:28.28~32.66个月),两组OS比较差异无统计学意义(P>0.05)。服用安罗替尼、初诊时复发或转移是PFS的独立影响因素。安罗替尼的不良反应主要为1~2级的食欲减退、乏力、粒细胞减少、高血压、手足皮肤反应、口腔黏膜炎以及肝功能损伤;3~4级不良反应发生率低,经对症处理和调整药物剂量后,大多数患者的不良反应可控制。结论口服安罗替尼靶向治疗联合GP方案化疗可延长复发或转移鼻咽癌患者的PFS,且安罗替尼相关不良反应大部分可耐受。
ObjectiveTo investigate the efficacy and safety of anlotinib combined with gemcitabine+cisplatin(GP)regimen in the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma.MethodsA retrospective case controlled study was conducted.The clinical data of 82 patients with nasopharyngeal carcinoma newly diagnosed as distant metastasis or recurrence and metastasis after radical chemoradiotherapy in the Second Affiliated Hospital of Guangxi University of Science and Technology and Laibin People's Hospital from January 2020 to December 2021 were retrospectively analyzed.Among 82 patients,45 patients receiving anlotinib combined with GP regimen were treated as the treatment group,and 37 patients receiving GP chemotherapy regimen during the same period were treated as the control group.Short-term efficacy and adverse reactions were compared between the 2 groups.Kaplan-Meier method was used to compare the progression-free survival(PFS)and overall survival(OS),and log-rank test was performed.Cox proportional risk model was used to analyze the factors influencing the PFS of patients.ResultsAmong 82 patients,63 were males and 19 were females,aged(48±10)years.The objective response rate(ORR)and disease control rate(DCR)in the treatment group were higher than those in the control group[ORR:71.11%(32/45)vs.62.16%(23/37);DCR:86.67%(39/45)vs.81.08%(30/37)],while there were no statistically significant differences(all P>0.05).The median PFS time was 23.53 months(95%CI:17.48-29.58 months),17.40 months(95%CI:13.33-21.47 months),respectively in the treatment group and the control group,and the difference in PFS was statistically significant(P<0.05).The median OS time was 34.03 months(95%CI:29.42-38.64 months),30.47 months(95%CI:28.28-32.66 months),respectively in the treatment group and the control group,and the difference in OS was not statistically significant(P>0.05).Oral anlotinib,recurrence or metastasis at initial diagnosis were independent factors influencing the PFS of patients.The main adverse effects of an
作者
蓝柳
韦婷婷
赵迎喜
梁立莉
龙亚秀
Lan Liu;Wei Tingting;Zhao Yingxi;Liang Lili;Long Yaxiu(Department of Radiotherapy 3,the Second Affiliated Hospital of Guangxi University of Science and Technology,Liuzhou 545006,China;Department of Oncology,Laibin People's Hospital,Laibin 546100,China)
出处
《肿瘤研究与临床》
CAS
2024年第8期604-609,共6页
Cancer Research and Clinic
基金
广西高校中青年教师科研基础能力提升项目(2020KY08030)
广西来宾市科学研究与技术开发计划(来科转202508)。
关键词
鼻咽肿瘤
复发
转移
安罗替尼
药物疗法
联合
Nasopharyngeal neoplasms
Recurrence
Metastasis
Anlotinib
Drug therapy,combination
